康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌的疗效观察
|
摘要
目的探讨康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌的临床疗效。方法选取2013年5月—2018年5月在洛阳市第三人民医院就诊的82例晚期非小细胞肺癌患者,随机分为观察组(n=41)和对照组(n=41)。对照组给予患者口服盐酸埃克替尼片,3次/d,125 mg/次。观察组在对照组基础上给予康艾注射液40 mL,1次/d。两组均治疗1个月。对比两组治疗效果、生活质量和毒副作用发生率。结果与对照组治疗总有效率12.20%和病情控制率48.78%比较,观察组治疗总有效率31.71%和病情控制率85.37%均显著升高(P<0.05)。两组呼吸困难、便秘、食欲缺乏发生率,角色功能、认知功能、社会功能评分及毒副作用(肝功能异常和腹泻)发生率比较,差异均无统计学意义。观察组疲倦、疼痛和皮疹发生率均显著低于对照组(P<0.05);躯体功能、情绪功能评分均显著高于对照组(P<0.05)。结论康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌疗效显著,且安全性良好,值得临床推广。
Objective To investigate the clinical efficacy of Kang Ai Injection combined with Icotinib Hydrochloride Tablets in the treatment of advanced non-small cell lung cancer(NSCLC). Methods 82 patients with advanced NSCLC from May 2013 to May2018 were randomly divided into observation group(icotinib hydrochloride + Kang Ai Injection, n = 41) and control group(icotinib hydrochloride, n = 41). The therapeutic effect, quality of life and incidence of side effects were compared between the two groups.Results The total effective rate 31.71% and disease control rate 85.37% in the observation group were significantly higher than those in the control group(12.20% & 48.78%)(P < 0.05). There was no significant difference in the incidence of dyspnea, constipation,anorexia, role function, cognitive function and social function score, incidence of toxic side effects(abnormal liver function and diarrhea) between the two groups. The incidence of fatigue, pain and rash in the observation group were significantly lower than those in the control group(P < 0.05), and the scores of physical function and emotional function were significantly higher than those in the control group(P < 0.05).Conclusion Kang Ai Injection combined with Icotinib Hydrochloride Tablets is effective and safe in the treatment of advanced NSCLC.
Objective To investigate the clinical efficacy of Kang Ai Injection combined with Icotinib Hydrochloride Tablets in the treatment of advanced non-small cell lung cancer(NSCLC). Methods 82 patients with advanced NSCLC from May 2013 to May2018 were randomly divided into observation group(icotinib hydrochloride + Kang Ai Injection, n = 41) and control group(icotinib hydrochloride, n = 41). The therapeutic effect, quality of life and incidence of side effects were compared between the two groups.Results The total effective rate 31.71% and disease control rate 85.37% in the observation group were significantly higher than those in the control group(12.20% & 48.78%)(P < 0.05). There was no significant difference in the incidence of dyspnea, constipation,anorexia, role function, cognitive function and social function score, incidence of toxic side effects(abnormal liver function and diarrhea) between the two groups. The incidence of fatigue, pain and rash in the observation group were significantly lower than those in the control group(P < 0.05), and the scores of physical function and emotional function were significantly higher than those in the control group(P < 0.05).Conclusion Kang Ai Injection combined with Icotinib Hydrochloride Tablets is effective and safe in the treatment of advanced NSCLC.
引文
[1]宋哲,胡毅.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床分析[J].中外医疗, 2018,37(21):90-92.
[2]王春凤,周爱军,徐肖.康艾注射液用于晚期非小细胞肺癌化疗后癌因性疲乏中的临床效果观察[J].中国实用医药, 2018, 13(20):90-92.
[3]庄毅.康艾注射液治疗中老年晚期非小细胞肺癌40例疗效观察[J].世界中医药, 2015, 10(11):1723-1725.
[4]王夏妮,田菲.中医药联合EGFR-TKIs治疗非小细胞肺癌的Meta分析[J].湖南中医药大学学报, 2018, 38(7):781-786.
[5]陈汉锐,田华琴,陈志明,等.康艾注射液联合单药化疗治疗老年晚期非小细胞肺癌的有效性和安全性[J].实用医学杂志, 2018, 34(2):316-319.
[6]王云,蒋雪,王莹.盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析[J].肿瘤学杂志, 2016, 22(3):176-179.
[7]周磊,邵燕儿,朱泽浩,等.华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学, 2018, 21(9):1047-1052.
[8]刘洪千,林宗斌,祁璘,等.康艾注射液联合常规化疗对晚期非小细胞肺癌患者免疫功能的影响及其疗效分析[J].肿瘤药学, 2017, 7(6):669-672+712.
[9]李波,董记刚,王守光,等.局部晚期非小细胞肺癌盐酸埃克替尼联合放疗及微波热疗临床观察[J].中华肿瘤防治杂志, 2017, 24(17):1232-1236.
[10]纪春东,于秀芹,赖永新.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].河北医学, 2017, 23(1):100-102.
[11]杨金霞,亓小改,田莹莹,等.盐酸埃克替尼治疗晚期复发非小细胞肺癌患者的临床疗效[J].中国肿瘤临床与康复, 2018, 25(6):645-647.
[12]田春艳,李馥郁,杨晋,等.盐酸埃克替尼一线治疗晚期非小细胞肺癌临床效果及对患者免疫功能影响[J].临床误诊误治, 2018, 31(8):64-68.
[13]杨君,郭晓辉,汪力慧.替吉奥联合康艾注射液治疗晚期非小细胞肺癌的疗效与安全性[J].海南医学, 2016,27(7):1073-1077.
[14]符少娘,林青,杨威,等.康艾注射液对非小细胞肺癌患者细胞、体液及红细胞免疫状态的影响研究[J].肿瘤药学, 2017, 7(4):431-435.
[15]周红,高亚洲.康艾注射液联合吉西他滨治疗非小细胞肺癌的临床研究[J].现代药物与临床, 2016, 31(7):1050-1054.
[16]张世才,张星星,康维娜,等.康艾注射液辅助序贯放化疗治疗晚期非小细胞肺癌的临床疗效探究[J].解放军医药杂志, 2016, 28(S1):50-52.
[2]王春凤,周爱军,徐肖.康艾注射液用于晚期非小细胞肺癌化疗后癌因性疲乏中的临床效果观察[J].中国实用医药, 2018, 13(20):90-92.
[3]庄毅.康艾注射液治疗中老年晚期非小细胞肺癌40例疗效观察[J].世界中医药, 2015, 10(11):1723-1725.
[4]王夏妮,田菲.中医药联合EGFR-TKIs治疗非小细胞肺癌的Meta分析[J].湖南中医药大学学报, 2018, 38(7):781-786.
[5]陈汉锐,田华琴,陈志明,等.康艾注射液联合单药化疗治疗老年晚期非小细胞肺癌的有效性和安全性[J].实用医学杂志, 2018, 34(2):316-319.
[6]王云,蒋雪,王莹.盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析[J].肿瘤学杂志, 2016, 22(3):176-179.
[7]周磊,邵燕儿,朱泽浩,等.华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学, 2018, 21(9):1047-1052.
[8]刘洪千,林宗斌,祁璘,等.康艾注射液联合常规化疗对晚期非小细胞肺癌患者免疫功能的影响及其疗效分析[J].肿瘤药学, 2017, 7(6):669-672+712.
[9]李波,董记刚,王守光,等.局部晚期非小细胞肺癌盐酸埃克替尼联合放疗及微波热疗临床观察[J].中华肿瘤防治杂志, 2017, 24(17):1232-1236.
[10]纪春东,于秀芹,赖永新.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].河北医学, 2017, 23(1):100-102.
[11]杨金霞,亓小改,田莹莹,等.盐酸埃克替尼治疗晚期复发非小细胞肺癌患者的临床疗效[J].中国肿瘤临床与康复, 2018, 25(6):645-647.
[12]田春艳,李馥郁,杨晋,等.盐酸埃克替尼一线治疗晚期非小细胞肺癌临床效果及对患者免疫功能影响[J].临床误诊误治, 2018, 31(8):64-68.
[13]杨君,郭晓辉,汪力慧.替吉奥联合康艾注射液治疗晚期非小细胞肺癌的疗效与安全性[J].海南医学, 2016,27(7):1073-1077.
[14]符少娘,林青,杨威,等.康艾注射液对非小细胞肺癌患者细胞、体液及红细胞免疫状态的影响研究[J].肿瘤药学, 2017, 7(4):431-435.
[15]周红,高亚洲.康艾注射液联合吉西他滨治疗非小细胞肺癌的临床研究[J].现代药物与临床, 2016, 31(7):1050-1054.
[16]张世才,张星星,康维娜,等.康艾注射液辅助序贯放化疗治疗晚期非小细胞肺癌的临床疗效探究[J].解放军医药杂志, 2016, 28(S1):50-52.